Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Operating Margin: 2022-2025

Historic Operating Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -30.85%.

  • Phathom Pharmaceuticals' Operating Margin rose 40210.00% to -30.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -145.03%, marking a year-over-year increase of 95099.00%. This contributed to the annual value of -502.18% for FY2024, which is 2403037.00% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Operating Margin is -30.85%, which was up 79.66% from -151.69% recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Operating Margin high stood at 1,373.90% for Q1 2022, and its period low was -10,245.60% during Q4 2023.
  • Over the past 3 years, Phathom Pharmaceuticals' median Operating Margin value was -200.30% (recorded in 2024), while the average stood at -1,367.56%.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Operating Margin tumbled by 1,073,135bps in 2023, and later spiked by 1,004,530bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Operating Margin (Quarterly) stood at 485.75% in 2022, then plummeted by 1,073,135bps to -10,245.60% in 2023, then soared by 1,004,530bps to -200.30% in 2024, then skyrocketed by 40,210bps to -30.85% in 2025.
  • Its Operating Margin was -30.85% in Q3 2025, compared to -151.69% in Q2 2025 and -276.53% in Q1 2025.